Vimarsana
Biggest News Aggregation in the World

Page 13 - Primary Prevention News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Primary Prevention. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Primary Prevention Today - Breaking & Trending Today

I have Cholesterol, Doctor! - Vimarsana News

I have Cholesterol, Doctor!

“I have Cholesterol” is a common complaint, often causing unwarranted stress and anxiety, particularly among young patients. When a patient begins the consultation with “I have Cholesterol”, my mind immediately goes back several decades in time to our prep school days, when we sang/shouted, in the dining hall, I scream You scream, We all scream […]

Source: island.lk
Ms. Cheap: Tennessee State Parks offer so much. Just ask Joan Payne - Vimarsana News

Ms. Cheap: Tennessee State Parks offer so much. Just ask Joan Payne

Joan Payne has visited 54 of the 56 Tennessee state parks.

Bending ethics to suit predetermined hypotheses – Prof Noakes on Ancel Keys' Cholesterol Con - Vimarsana News

Bending ethics to suit predetermined hypotheses – Prof Noakes on Ancel Keys' Cholesterol Con

Noakes continues with Keys' cholesterol con kicking off with the Report of the Inter-Society Commission for Heart Disease Resources in 1970.

Novartis Pharma AG: New long-term Leqvio (inclisiran) data from Novartis show sustained efficacy and safety over four years - Vimarsana News

Novartis Pharma AG: New long-term Leqvio (inclisiran) data from Novartis show sustained efficacy and safety over four years

Results from ORION-3 open-label trial show twice-yearly* Leqvio(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol (LDL-C)

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years - Vimarsana News

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years

Investegate announcements from NOVARTIS AG CHF0.50(REGD), New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years